Proton Therapy
Middle East · 1 shared keyword
Updated
Reviewed by Chandani Patel
Middle East Hereditary Cancer Testing Market Industry Trends and Forecast to 2034: Segmented by (Cancer, Test, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$313.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $181.4 Mn | — | — |
| 2025 (base) | $201.3 Mn | +$20.0 Mn | — |
| 2026 (forecast) | $223.5 Mn | +$22.1 Mn | +11% |
| 2027 (forecast) | $248.1 Mn | +$24.6 Mn | +23.2% |
| 2028 (forecast) | $275.3 Mn | +$27.3 Mn | +36.8% |
| 2029 (forecast) | $305.6 Mn | +$30.3 Mn | +51.8% |
| 2030 (forecast) | $339.2 Mn | +$33.6 Mn | +68.5% |
| 2031 (forecast) | $376.6 Mn | +$37.3 Mn | +87% |
| 2032 (forecast) | $418.0 Mn | +$41.4 Mn | +107.6% |
| 2033 (forecast) | $464.0 Mn | +$46.0 Mn | +130.5% |
| 2034 (forecast) | $515.0 Mn | +$51.0 Mn | +155.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $201.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $515.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Cancer, test and end user (see all) |
| Key players | Myriad Genetics, Inc., Ambry Genetics, Invitae, Natera, Quest Diagnostics (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Hereditary cancer testing looks for inherited gene changes, such as BRCA1 and BRCA2, that raise the risk of cancer.
Key segments of the hereditary Cancer Testing market include cancer (Breast and Ovarian, Colorectal (Lynch Syndrome) and Prostate) and test (Multi-Gene Panels, BRCA Tests and Whole Exome).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the hereditary Cancer Testing market.
Routine use of genomics in screening, pharmacy and primary care gives the hereditary Cancer Testing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the hereditary Cancer Testing market.
The hereditary Cancer Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how hereditary Cancer Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Middle East.
What doctors and scientists are doing in Hereditary Cancer Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East
Middle East
Pharmaceuticals · Middle East
Digital Health · Middle East
Healthcare Services · Middle East
Pharmaceuticals · Middle East
Pharmaceuticals · Middle East
Healthcare Services · Middle East